On a broader view, it is reasonable to speculate that meticrane may not alter any specific cancer-related pathway, but may exert its distant effects on the cancer cells (passively) via well-known immune-regulatory/epigenetic signaling pathways, preferably via targeting PD-L1, TIM-3, CD73, and HDACs. This evidence concerns the gene CD274 and cancer.